Literature DB >> 19139010

Retinoid chemoprevention trials: cyclin D1 in the crosshairs.

Sarah J Freemantle1, Yongli Guo, Ethan Dmitrovsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19139010      PMCID： PMC3963159          DOI： 10.1158/1940-6207.CAPR-08-0218

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN： 1940-6215


× No keyword cloud information.
  46 in total

1.  Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells.

Authors:  Deborah A Greer Card; Pratibha B Hebbar; Leping Li; Kevin W Trotter; Yoshihiro Komatsu; Yuji Mishina; Trevor K Archer
Journal:  Mol Cell Biol       Date:  2008-08-18       Impact factor: 4.272

2.  Assessing efficacy in early-phase cancer prevention trials: the case of oral premalignancy.

Authors:  Eva Szabo
Journal:  Cancer Prev Res (Phila)       Date:  2008-10

3.  Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.

Authors:  S M Lippman; J J Lee; D D Karp; E E Vokes; S E Benner; G E Goodman; F R Khuri; R Marks; R J Winn; W Fry; S L Graziano; D R Gandara; G Okawara; C L Woodhouse; B Williams; C Perez; H W Kim; R Lotan; J A Roth; W K Hong
Journal:  J Natl Cancer Inst       Date:  2001-04-18       Impact factor: 13.506

4.  Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma.

Authors:  K Bani-Hani; I G Martin; L J Hardie; N Mapstone; J A Briggs; D Forman; C P Wild
Journal:  J Natl Cancer Inst       Date:  2000-08-16       Impact factor: 13.506

5.  Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma.

Authors:  Robert W Chen; Lynne T Bemis; Carol M Amato; Han Myint; Hung Tran; Diane K Birks; S Gail Eckhardt; William A Robinson
Journal:  Blood       Date:  2008-05-15       Impact factor: 22.113

6.  Cyclin D1 and cancer development in laryngeal premalignancy patients.

Authors:  Vassiliki Papadimitrakopoulou; Julie G Izzo; Diane D Liu; Jeffrey Myers; Tania L Ceron; Jan Lewin; William N William; Anthea Atwell; J Jack Lee; Ann Gillenwater; Adel El-Naggar; Xifeng Wu; Scott M Lippman; Walter N Hittelman; Waun Ki Hong
Journal:  Cancer Prev Res (Phila)       Date:  2009-01

7.  High-dose fenretinide in oral leukoplakia.

Authors:  William N William; J Jack Lee; Scott M Lippman; Jack W Martin; Nitin Chakravarti; Hai T Tran; Anita L Sabichi; Edward S Kim; Lei Feng; Reuben Lotan; Vassiliki A Papadimitrakopoulou
Journal:  Cancer Prev Res (Phila)       Date:  2009-01

8.  Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis.

Authors:  Noel Pabalan; Bharati Bapat; Lillian Sung; Hamdi Jarjanazi; Ofelia Francisco-Pabalan; Hilmi Ozcelik
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10       Impact factor: 4.254

9.  miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes.

Authors:  Qin Liu; Hanjiang Fu; Fang Sun; Haoming Zhang; Yi Tie; Jie Zhu; Ruiyun Xing; Zhixian Sun; Xiaofei Zheng
Journal:  Nucleic Acids Res       Date:  2008-08-13       Impact factor: 16.971

10.  A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation.

Authors:  Zuoren Yu; Chenguang Wang; Min Wang; Zhiping Li; Mathew C Casimiro; Manran Liu; Kongming Wu; James Whittle; Xiaoming Ju; Terry Hyslop; Peter McCue; Richard G Pestell
Journal:  J Cell Biol       Date:  2008-08-11       Impact factor: 10.539
View more
  3 in total

1.  Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model.

Authors:  Jangsoon Lee; Seung-Hee Ryu; Shin Myung Kang; Wen-Cheng Chung; Kathryn Ann Gold; Edward S Kim; Walter N Hittelman; Waun Ki Hong; Ja Seok Koo
Journal:  Cancer Prev Res (Phila)       Date:  2011-04-19

2.  Evidence for the ubiquitin protease UBP43 as an antineoplastic target.

Authors:  Yongli Guo; Fadzai Chinyengetere; Andrey V Dolinko; Alexandra Lopez-Aguiar; Yun Lu; Fabrizio Galimberti; Tian Ma; Qing Feng; David Sekula; Sarah J Freemantle; Angeline S Andrew; Vincent Memoli; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2012-07-02       Impact factor: 6.261

3.  Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile.

Authors:  Sanjida Mahjabeen; Manolya Kukut Hatipoglu; Stanley D Kosanke; David Garcia-Contreras; Doris M Benbrook; Lucila Garcia-Contreras
Journal:  J Pharm Sci       Date:  2020-02-27       Impact factor: 3.534
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.